ONTX - Could Breakout, How Far?All,
ONTX is overdue for a takeoff. Today it is at +30% premarket, but this is why you do TA and watch Volume at open. It will gap above both blue lines for support and .44/.45 are aboth huge support lines. My theory is simple it may sell off around .53. However, I would hold and wait for the rally at .39 or .44 to push back up to .70-.75. The question there becomes will it break or fail that area on second re test?
ALSO FIRST THING IS FIRST WATCH THE MARKET BEFORE YOU BUY ANY STOCK. S&P / NASDAQ AND WATCH VOLUME ON INVERSE S&P ETFS.
BIOCON
VXRT - Big Moves AheadAll,
This may drop to $2.30-2.50 but after that should be a move up. We are moving into a previous consolidation area. The news etc outlook prior to the virus all look like it should move up. However, you never know so keep an eye out of course. We should see some movement this week for sure.
#BIOCONBIOCON
Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 5005
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.
Biocon Short"Biocon is expensive as compare to its competitors and its trading above its sector's PE ratio which is 50.65. biocon PE ratio is 64.71 which is alot higher than other pharma companies who is trading below PE ratio of 30. it will get its fair value soon. Advice : Stay short.
Resting on Retracement 583.85 - Next Target 669.50SL 557.35
if closes monthly above 669.50, Then next target 808
CCI34 Monthly is still above 100
CCI8 is below 0 - Nice Retracement view, must jump from here.
SHORT BIOCON - SHORTING SETUPThe price action is been trading in a leading diagonal pattern which is now indicating weakness as higher prices rejected by sellers and sellers are now in dominance.
I would suggest to short this one on every rise.
Target 1: 850
Target 2: 825
Stoploss: 940
Trade with care, thanks for your support.
Short BIOCONBit late in publishing this idea. Call was given at 725 level and its already down to 704,but further downside expected upto 650 levels easily.
Engulfing candle has also appeared, which has reinforced the view. At 650, it will complete FIB retracement of 38%.
